188 related articles for article (PubMed ID: 24231406)
21. Development of a highly stable and targetable nanoliposomal formulation of topotecan.
Drummond DC; Noble CO; Guo Z; Hayes ME; Connolly-Ingram C; Gabriel BS; Hann B; Liu B; Park JW; Hong K; Benz CC; Marks JD; Kirpotin DB
J Control Release; 2010 Jan; 141(1):13-21. PubMed ID: 19686789
[TBL] [Abstract][Full Text] [Related]
22. Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation.
Liu JJ; Hong RL; Cheng WF; Hong K; Chang FH; Tseng YL
Anticancer Drugs; 2002 Aug; 13(7):709-17. PubMed ID: 12187327
[TBL] [Abstract][Full Text] [Related]
23. Quantification of Unencapsulated Drug in Target Tissues Demonstrates Pharmacological Properties and Therapeutic Effects of Liposomal Topotecan (FF-10850).
Kimura T; Okada K; Morohashi Y; Kato Y; Mori M; Kato H; Matsumoto T; Shimoyama S
Pharm Res; 2024 Apr; 41(4):795-806. PubMed ID: 38536615
[TBL] [Abstract][Full Text] [Related]
24. Optimization of liposomal topotecan for use in treating neuroblastoma.
Chernov L; Deyell RJ; Anantha M; Dos Santos N; Gilabert-Oriol R; Bally MB
Cancer Med; 2017 Jun; 6(6):1240-1254. PubMed ID: 28544814
[TBL] [Abstract][Full Text] [Related]
25. Comparative brain tissue distribution of camptothecin and topotecan in the rat.
El-Gizawy SA; Hedaya MA
Cancer Chemother Pharmacol; 1999; 43(5):364-70. PubMed ID: 10100590
[TBL] [Abstract][Full Text] [Related]
26. In vitro and in vivo studies of different liposomes containing topotecan.
Hao YL; Deng YJ; Chen Y; Wang XM; Zhong HJ; Suo XB
Arch Pharm Res; 2005 May; 28(5):626-35. PubMed ID: 15974453
[TBL] [Abstract][Full Text] [Related]
27. Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan.
Subramanian D; Muller MT
Oncol Res; 1995; 7(9):461-9. PubMed ID: 8835290
[TBL] [Abstract][Full Text] [Related]
28. Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release.
Souza LG; Silva EJ; Martins AL; Mota MF; Braga RC; Lima EM; Valadares MC; Taveira SF; Marreto RN
Eur J Pharm Biopharm; 2011 Sep; 79(1):189-96. PubMed ID: 21352915
[TBL] [Abstract][Full Text] [Related]
29. Topotecan hydrochloride liposomes incorporated into thermosensitive hydrogel for sustained and efficient in situ therapy of H22 tumor in Kunming mice.
Xing J; Qi X; Jiang Y; Zhu X; Zhang Z; Qin X; Wu Z
Pharm Dev Technol; 2015 Nov; 20(7):812-819. PubMed ID: 24909735
[TBL] [Abstract][Full Text] [Related]
30. Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine.
Burke TG; Gao X
J Pharm Sci; 1994 Jul; 83(7):967-9. PubMed ID: 7965676
[TBL] [Abstract][Full Text] [Related]
31. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH.
Gabr A; Kuin A; Aalders M; El-Gawly H; Smets LA
Cancer Res; 1997 Nov; 57(21):4811-6. PubMed ID: 9354443
[TBL] [Abstract][Full Text] [Related]
32. Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts.
Yamashita Y; Krauze MT; Kawaguchi T; Noble CO; Drummond DC; Park JW; Bankiewicz KS
Neuro Oncol; 2007 Jan; 9(1):20-8. PubMed ID: 17018695
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of the fraction of the active form of an antitumor drug topotecan via an injectable hydrogel.
Chang G; Ci T; Yu L; Ding J
J Control Release; 2011 Nov; 156(1):21-7. PubMed ID: 21777632
[TBL] [Abstract][Full Text] [Related]
34. Binding of topotecan to chromatin: Insights into cooperative binding and comparison with DNA.
Babaei M; Rabbani-Chadegani A; Ghadam P
Int J Biol Macromol; 2015 Sep; 80():57-63. PubMed ID: 26092169
[TBL] [Abstract][Full Text] [Related]
35. Modified hydrolysis kinetics of the active lactone moiety of 10-hydroxycamptothecin by liposomal encapsulation.
Shi K; Tian Y; Jiang Y; Wang L; Cui F
Pharm Dev Technol; 2010 Dec; 15(6):644-52. PubMed ID: 19943738
[TBL] [Abstract][Full Text] [Related]
36. Dynamic, nonsink method for the simultaneous determination of drug permeability and binding coefficients in liposomes.
Fugit KD; Anderson BD
Mol Pharm; 2014 Apr; 11(4):1314-25. PubMed ID: 24628304
[TBL] [Abstract][Full Text] [Related]
37. Microbore HPLC method with online microdialysis for measurement of topotecan lactone and carboxylate in murine CSF.
Leggas M; Zhuang Y; Welden J; Self Z; Waters CM; Stewart CF
J Pharm Sci; 2004 Sep; 93(9):2284-95. PubMed ID: 15295789
[TBL] [Abstract][Full Text] [Related]
38. Preparation, optimization, and characterization of topotecan loaded PEGylated liposomes using factorial design.
Vali AM; Toliyat T; Shafaghi B; Dadashzadeh S
Drug Dev Ind Pharm; 2008 Jan; 34(1):10-23. PubMed ID: 18214751
[TBL] [Abstract][Full Text] [Related]
39. Clinical pharmacokinetics of topotecan.
Herben VM; ten Bokkel Huinink WW; Beijnen JH
Clin Pharmacokinet; 1996 Aug; 31(2):85-102. PubMed ID: 8853931
[TBL] [Abstract][Full Text] [Related]
40. Revisiting the nanoformulation design approach for effective delivery of topotecan in its stable form: an appraisal of its in vitro Behavior and tumor amelioration potential.
Padhi S; Mirza MA; Verma D; Khuroo T; Panda AK; Talegaonkar S; Khar RK; Iqbal Z
Drug Deliv; 2016 Oct; 23(8):2827-2837. PubMed ID: 26548664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]